What are the risks of using research peptides on yourself? What FDA and CDC report

Research-use-only peptides are not made, tested or approved for people; this page sets out the risks FDA and CDC describe and where to get help if something goes wrong.

Basics7 min read

Key takeaway

A "research use only" label tells you what a product was sold for. It says nothing about whether the product is safe in a person. FDA says it lacks the information to know whether several popular research peptides would cause harm in humans. FDA and CDC describe further risks: unknown or impure contents, immune reactions, infection and dosing errors. Many peptides are also banned in sport. If something goes wrong, call 911 or Poison Help at 1-800-222-1222.

At a glance

Article typeBasics
TopicLaw & regulation
Studies cited1
Related productsResearch peptide catalog

Some people searching research peptides want to know whether they can use them on themselves. Research-use-only peptides are labeled for laboratory research, not for human or veterinary use. No research-grade product is FDA-approved for use in people. This page sets out the risks FDA, CDC and others have documented, and what to do if something goes wrong. It gives no instructions of any kind. Sources were checked on November 17, 2026.

Quick answer: Research-use-only peptides are not meant to be used in people, and none is FDA-approved for human use. FDA describes risks that include unknown quality, wrong or harmful ingredients, impurities and immune reactions. CDC warns that unsafe injections can spread hepatitis and other infections. If you feel unwell after using one, call 911 in an emergency or Poison Help at 1-800-222-1222, and tell a clinician.

What does "research use only" mean?

A "research use only" label states the seller's intended use: laboratory research, not use in people or animals. It is not an approval, and it is not a safety finding. Research-grade peptides are laboratory reagents. They are not medicines and not a substitute for one.

The label also does not settle the legal question by itself. FDA judges a product's intended use from labeling, advertising and the circumstances of sale (21 CFR 201.128). FDA has warned sellers whose research-labeled products were "sold directly to consumers for human use with dosing instructions" (FDA, 2026). See what research use only means and FDA warning letters to peptide sellers.

Has FDA found research peptides safe for people?

No. When several peptides were nominated for pharmacy compounding, FDA reviewed what was known about them and published its concerns (FDA, 2026). For BPC-157, FDA wrote that it "lacks sufficient information to know whether the drug would cause harm" in humans. For MOTS-c and TB-500, FDA said it had found no human exposure data. For CJC-1295, it identified serious adverse events, including increased heart rate.

Our page on why research peptides have no dose sets these findings out compound by compound.

What risks do FDA and CDC describe?

Table 1 summarizes the main risks and who documented them. The sections below explain each one in plain terms.

Table 1

Documented risks of using research or unapproved peptide products in people (checked November 17, 2026)

Risk What the source says Source
Wrong or harmful contents Illegally marketed drugs sold online could contain "the wrong ingredients or harmful ingredients" or "too little, too much or no active ingredient at all" FDA, 2026
Impurities and endotoxin Semaglutide vials bought online without a prescription had low purity, and endotoxin was found in every sample Ashraf et al., 2024
Immune reactions Compounded drugs containing BPC-157, TB-500, MOTS-c and other peptides "may pose risk for immunogenicity" FDA, 2026
Infection Unsafe injections "can spread diseases like hepatitis C, hepatitis B, bacterial and fungal diseases" CDC, 2024
Dosing errors Adverse events, some requiring hospitalization, after patients drew up more than prescribed from multiple-dose vials FDA, 2024
Sport sanctions BPC-157, TB-500, CJC-1295, ipamorelin and other peptides are prohibited at all times WADA, 2026

Wrong, impure or contaminated contents

A vial's label is only as good as the process behind it. FDA warns that illegally marketed drugs sold online may be counterfeit or hold the wrong amount of the right ingredient (FDA, 2026). It calls research-labeled GLP-1 products sold for human use "of unknown quality." A 2024 study tested semaglutide vials bought online without a prescription. Their content did not match the label and purity was far below the claim. Every sample contained endotoxin, a bacterial toxin (Ashraf et al., 2024).

Approved medicines meant to be sterile or pyrogen-free must be tested batch by batch under FDA's manufacturing rules (21 CFR 211.167). A research-use label makes no such promise. Our guide to endotoxin testing explains what that lab test measures.

Immune reactions

Immunogenicity means the immune system may react to a peptide or to impurities that come with it. FDA lists this as a concern for most of the peptides it reviewed, often citing "aggregation" and "peptide-related impurities" (FDA, 2026).

Infection

CDC says the reuse of needles or syringes and the misuse of medication vials are unsafe injection practices. It warns that unsafe injections can spread hepatitis C, hepatitis B, and bacterial and fungal diseases (CDC, 2024). That risk exists even before the question of what is in the vial.

Dosing errors

FDA has reported adverse events, some needing hospital care, linked to dosing errors with compounded semaglutide. Patients drew up too much from multiple-dose vials, and some clinicians miscalculated doses. FDA also pointed to confusion between units of measurement (FDA, 2024). Those errors happened with prescribed products that came with directions. Research material has no approved directions at all.

Drug testing and sport

WADA's 2026 Prohibited List names BPC-157 under S0, non-approved substances. It names CJC-1295, ipamorelin, sermorelin, tesamorelin and TB-500 under S2. All are "prohibited at all times," in and out of competition (WADA, 2026). Athletes should check any substance with their anti-doping organization. See peptides on the 2026 WADA list.

What should you do if something goes wrong?

  1. In an emergency, call 911. MedlinePlus advises calling your local emergency number, such as 911, after a harmful exposure (MedlinePlus, 2025).
  2. Call Poison Help at 1-800-222-1222. It is free and confidential, open 24 hours a day, 7 days a week, and the call does not need to be an emergency (MedlinePlus, 2025).
  3. Tell a clinician exactly what you used. Keep the product and its packaging so a doctor or pharmacist can see the label.
  4. Report it to FDA. MedWatch takes reports of serious reactions, product quality problems and product use errors. Report online or call 1-888-INFO-FDA (1-888-463-6332) and press 2 (FDA, 2025).

Where can you get legitimate care instead?

Frequently asked questions about research peptide risks

Can research-use-only peptides be used in people?

No. They are labeled for laboratory research only, not for human or veterinary use, and none is FDA-approved for use in people.

What are the risks of injecting research peptides?

FDA and CDC describe unknown or wrong contents, impurities and endotoxin, immune reactions, infection and dosing errors. FDA also says it lacks the information to know whether several research peptides would cause harm.

How do you inject or take BPC-157?

We do not give injection or use instructions for BPC-157 or any peptide. BPC-157 is not an approved drug, and FDA says it lacks the information to know whether it would harm people.

How do I report a side effect or a bad product to the FDA?

Use FDA's MedWatch program online at contact.fda.gov/report-problem, or call 1-888-INFO-FDA (1-888-463-6332) and press 2. MedWatch accepts reports of serious reactions, quality problems and use errors.

What should I do if I feel unwell after using a peptide?

Call 911 in an emergency. Otherwise call Poison Help at 1-800-222-1222, which is free, confidential and open 24 hours a day, and tell a clinician what you used.

Do peptides show up on a drug test?

We do not discuss detection. What matters is status: WADA's 2026 list prohibits BPC-157, TB-500, CJC-1295, ipamorelin and other peptides at all times.

What to know now

  • Research use only: a label for laboratory work, not a safety finding or permission for human use.
  • FDA's view: for several research peptides, FDA lacks the information to know whether they would cause harm.
  • Documented risks: wrong contents, impurities and endotoxin, immune reactions, infection and dosing errors.
  • Sport: many peptides are prohibited at all times under WADA's 2026 list.
  • Help: 911, Poison Help at 1-800-222-1222, a clinician, and FDA MedWatch.

What we're watching

New FDA safety communications and warning letters about research-labeled peptides, any FDA decision on peptides for the 503A bulks list, and WADA's 2027 Prohibited List.

Also in the library

Sources: Code of Federal Regulations. 21 CFR 201.128: Meaning of "intended uses" . https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-E/section-201.128, 21 CFR 201.128: Meaning of "intended uses"; U.S. Food and Drug Administration 2026, FDA's concerns with unapproved GLP-1 drugs used for weight loss; U.S. Food and Drug Administration 2026; Ashraf 2024, Journal of Medical Internet Research; Code of Federal Regulations. 21 CFR 211.167: Special testing requirements . https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-I/section-211.167, 21 CFR 211.167: Special testing requirements; Centers for Disease Control and Prevention 2024, About injection safety; U.S. Food and Drug Administration 2024; World Anti-Doping Agency 2025, World Anti-Doping Code International Standard: Prohibited List 2026; National Library of Medicine 2025, MedlinePlus: Poisoning first aid; National Library of Medicine 2025, MedlinePlus: Poison control center, emergency number; U.S. Food and Drug Administration 2025, Reporting serious problems to FDA; U.S. Food and Drug Administration. MedWatch online reporting form . https://contact.fda.gov/report-problem, MedWatch online reporting form; U.S. Food and Drug Administration. BeSafeRx: Your source for online pharmacy information . https://www.fda.gov/drugs/buying-using-medicine-safely/besaferx-your-source-online-pharmacy-information, BeSafeRx: Your source for online pharmacy information; U.S. National Library of Medicine. ClinicalTrials.gov . https://clinicaltrials.gov/, ClinicalTrials.gov. All 14 citations

Back to the research library

References

  1. Code of Federal Regulations. 21 CFR 201.128: Meaning of "intended uses". https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-E/section-201.128
  2. U.S. Food and Drug Administration. (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  3. U.S. Food and Drug Administration. (2026). Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  4. Ashraf, A. R., Mackey, T. K., Vida, R. G., et al. (2024). Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription. Journal of Medical Internet Research, 26, e65440. https://pubmed.ncbi.nlm.nih.gov/39509151/
  5. Code of Federal Regulations. 21 CFR 211.167: Special testing requirements. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-I/section-211.167
  6. Centers for Disease Control and Prevention. (2024). About injection safety. https://www.cdc.gov/injection-safety/about/index.html
  7. U.S. Food and Drug Administration. (2024). FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
  8. World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026 (in effect January 1, 2026). https://www.wada-ama.org/en/prohibited-list
  9. National Library of Medicine. (2025). MedlinePlus: Poisoning first aid (reviewed January 8, 2025). https://medlineplus.gov/ency/article/007579.htm
  10. National Library of Medicine. (2025). MedlinePlus: Poison control center, emergency number (reviewed January 8, 2025). https://medlineplus.gov/ency/article/002724.htm
  11. U.S. Food and Drug Administration. (2025). Reporting serious problems to FDA (content current as of September 26, 2025). https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda
  12. U.S. Food and Drug Administration. MedWatch online reporting form. https://contact.fda.gov/report-problem
  13. U.S. Food and Drug Administration. BeSafeRx: Your source for online pharmacy information. https://www.fda.gov/drugs/buying-using-medicine-safely/besaferx-your-source-online-pharmacy-information
  14. U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/